St. Louis biotech startup Wugen inks licensing deal, hires new C-suite exec
St. Louis Business Journal, Nathan Rubbelke, February 2021
Articles
Press Releases
Wugen Announces Exclusive License Agreement for their Memory Natural Killer (NK) Cell-based Therapy Program with Washington University in St. Louis
ST. LOUIS, MO, February 22, 2021 /PRNewswire/ – Wugen Inc., a biotechnology company developing novel, universal allogeneic cellular therapies, today
Press Releases
Wugen Appoints Jan Davidson M.D., Ph.D., as Chief Medical Officer to Guide the Company’s Global NK and T cell Clinical Programs
ST. LOUIS, February 22, 2021 – Wugen Inc., a biotechnology company developing novel, universal allogeneic off-the-shelf cell therapies, today announced
Articles
Wugen Ramps Up Off-the-Shelf Gene Therapies to Fight Cancer
Biospace, Kate Goodwin, January 2021
Scientific Publications
Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia
Cancer Discovery, Berrien-Elliott et al, December 2020
Press Releases
Wugen Appoints New Vice President and Head of NK Research as the Company Continues to Expand its Pipeline
ST. LOUIS, Nov. 19, 2020 /PRNewswire/ — Wugen Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced the
Scientific Publications
CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas
Blood, Gang et al, November 2020
Scientific Publications
Memory-like natural killer cells for cancer immunotherapy
Seminars in Hematology, Gang et al, November 2020
Scientific Publications
Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies
Best Practice & Research Clinical Haematology, Cooper and DiPersio, December 2019
Press Releases
Wugen Adds to Leadership Team as Company Continues to Lay Groundwork for Future Expansion
ST. LOUIS, April 30, 2019 /PRNewswire/ — Wugen Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced